Dr Thomas Bachelot is careful to set reasonable expectations for his patients with HR+/HER2- metastatic breast cancer regarding how long their treatment will last and how it will impact them.
Get TOP in Your Inbox
Stay up to date with the latest oncology pharmacy news and insights by subscribing to our e-newsletter!
